Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OSMITROL 10% IN WATER IN PLASTIC CONTAINER vs MANNITOL 10%
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Increases plasma osmolality, drawing water from tissues into the bloodstream, thereby reducing intracranial pressure and cerebral edema.
Mannitol is an osmotic diuretic that increases urinary output by raising the osmolarity of glomerular filtrate, thereby reducing tubular reabsorption of water and solutes. It also reduces cerebral edema by creating an osmotic gradient across the blood-brain barrier, drawing water from brain tissue into plasma.
Reduction of intracranial pressure,Reduction of cerebral edema,Promotion of diuresis in oliguric phase of acute renal failure
Reduction of intracranial pressure and cerebral edema,Promotion of diuresis in patients with acute renal failure (oliguric phase) or to prevent renal failure in certain conditions,Reduction of intraocular pressure in acute glaucoma,Enhancement of urinary excretion of toxic substances (e.g., in overdoses),Adjunct in dialysis or hemofiltration (off-label)
Initial: 0.25–1 g/kg (25–100 m L of 10% solution) IV over 30–60 minutes. May repeat every 6–12 hours if needed. Typical adult dose: 50–100 g IV. Maximum: 2 g/kg per dose.
0.25-2 g/kg intravenously as a 10% solution over 30-60 minutes, typically 50-100 g every 6-8 hours.
Terminal half-life approximately 1.5 hours in normal renal function; prolonged in renal impairment (up to 36 hours in anuria).
Terminal half-life: 1.1–1.6 hours; prolonged to 6–36 hours in renal impairment
Primarily excreted unchanged by the kidneys; not metabolized.
Mannitol is not metabolized in the body. It is eliminated unchanged by the kidneys via glomerular filtration with minimal tubular reabsorption.
Primarily renal; >90% excreted unchanged in urine via glomerular filtration; <5% biliary/fecal.
Renal: 90% as unchanged drug; <10% metabolized in liver to fructose and glucose; fecal: negligible
Negligible (<10%); does not significantly bind to plasma proteins.
Negligible (<2%); does not bind to plasma proteins
Vd ~0.5 L/kg; distributes primarily in extracellular fluid, excluding cells.
0.36–0.5 L/kg; distributes primarily in extracellular fluid, limited CNS penetration due to hydrophilic nature
Not applicable (administered intravenously only); bioavailability is 100% by IV route.
IV: 100%; oral: negligible (<10%) due to poor absorption and osmotic diarrhea
Contraindicated in anuria or severe renal impairment (GFR <10 m L/min). In patients with GFR 10–50 m L/min, reduce dose by 50% and monitor serum osmolarity and urine output. Do not use if oliguria persists after test dose (0.2 g/kg IV over 3–5 minutes).
Contraindicated in anuria or severe renal impairment (GFR < 20 m L/min). For GFR 20-50 m L/min, reduce dose by 50% and monitor serum osmolality.
No specific Child-Pugh based adjustment. Use with caution in severe hepatic impairment due to potential for fluid overload and electrolyte disturbances. Monitor serum electrolytes and hepatic function.
No specific Child-Pugh based adjustment required; use with caution in severe hepatic impairment due to risk of fluid overload.
Oliguria: Test dose 0.2 g/kg (2 m L/kg of 10% solution) IV over 3–5 minutes. If urine output >40 m L/hr, maintenance dose: 0.25–1 g/kg (2.5–10 m L/kg) IV over 30–60 minutes every 6–12 hours. Maximum: 2 g/kg per dose. Reduce intracranial pressure: 0.25–1 g/kg IV over 30–60 minutes.
0.25-1 g/kg intravenously as a 10% solution over 30-60 minutes, repeated every 6-8 hours as needed.
Start at lower end of dosing range (0.25 g/kg) due to age-related decline in renal function. Monitor renal function, serum osmolarity, electrolytes (especially sodium and potassium), and fluid balance closely. Avoid use if GFR <50 m L/min unless benefit outweighs risk.
Start at lower end of dosing range (0.25-0.5 g/kg) due to decreased renal function; monitor fluid and electrolyte balance closely.
Not approved for use in patients with severe renal impairment, anuria, or intracranial hemorrhage with active bleeding.
None
Monitor renal function, fluid and electrolyte balance, and serum osmolality. Use caution in patients with cardiac or pulmonary congestion, and administer via a filter to prevent crystallization.
Use with caution in patients with congestive heart failure due to risk of pulmonary edema from fluid overload,Monitor serum electrolytes (especially sodium and potassium) and renal function during therapy,May cause acute kidney injury with excessive doses or pre-existing renal impairment,In patients with intracranial hemorrhage, avoid rapid reduction of intracranial pressure,May cause expansion of extracellular fluid volume leading to pulmonary edema in patients with compromised cardiac function
Anuria, severe renal impairment, pulmonary congestion, active intracranial hemorrhage, severe dehydration, known hypersensitivity to mannitol.
Anuria due to severe renal disease,Severe pulmonary edema or congestion,Active intracranial bleeding (except during craniotomy),Severe dehydration,Hypersensitivity to mannitol
No specific food interactions. Maintain adequate hydration as directed. Avoid excessive salt intake to minimize fluid retention.
Avoid high-sodium foods and salt substitutes to prevent electrolyte imbalance; maintain adequate fluid intake unless fluid restriction is advised; no specific food interactions, but monitor for changes in blood glucose if diabetic.
Osmitrol 10% (mannitol) is a hyperosmolar agent. There are no adequate and well-controlled studies in pregnant women. Animal studies have not been conducted. In first trimester, use only if clearly needed. In second and third trimesters, mannitol can cross the placenta and may cause fetal dehydration, electrolyte disturbances, and osmotic shifts. Risk cannot be excluded.
Mannitol is a pregnancy category C drug. First trimester: Limited human data; animal studies indicate potential for fetal harm at high doses due to osmotic effects, but risk with clinical use is low. Second trimester: Generally safe for short-term use when indicated (e.g., elevated intracranial pressure), but avoid prolonged exposure to prevent fetal dehydration or electrolyte imbalances. Third trimester: Use cautiously; osmotic diuresis may cause maternal hypovolemia, potentially reducing placental perfusion and leading to fetal distress.
It is not known whether mannitol is excreted in human breast milk. No M/P ratio is available. Caution should be exercised when administered to a nursing woman. Consider the developmental and health benefits of breastfeeding alongside the mother's clinical need for the drug.
Mannitol is excreted into breast milk in low concentrations (estimated M/P ratio <0.1) due to its high molecular weight and hydrophilicity. Oral bioavailability in infants is negligible, and no adverse effects have been reported. However, caution is advised if used repeatedly or in high doses, as theoretical risk of neonatal electrolyte imbalance exists.
Pregnancy increases glomerular filtration rate, which may enhance mannitol elimination, but dosage adjustments are not established. Maintain standard dosing (generally 50-200 g over 24 hours). Monitor clinical response and urine output. No routine pharmacokinetic-based dose adjustment recommended.
Pregnancy does not significantly alter the pharmacokinetics of mannitol. Standard adult dosing (0.25–2 g/kg as a 10% solution) is recommended, with adjustments based on renal function, volume status, and therapeutic response. Avoid excessive doses to prevent maternal volume overload and electrolyte disturbances.
Osmítrol 10% is a hyperosmotic agent used to reduce intracranial pressure and cerebral edema. Administer via IV infusion using an in-line filter to prevent particulate embolism. Monitor serum osmolarity and sodium levels; discontinue if osmolarity exceeds 320 m Osm/L. Ensure adequate hydration to avoid hypovolemia. Use with caution in patients with renal impairment, congestive heart failure, or pulmonary congestion. Crystallization may occur at low temperatures; warm to redissolve crystals before use.
Administer via in-line filter to prevent crystallization; monitor serum sodium and osmolality closely to avoid hypernatremia and osmotic demyelination; ensure adequate urine output before use to avoid pulmonary edema; use with caution in patients with congestive heart failure or renal impairment; can cause transient volume expansion followed by diuresis.
This medication is given intravenously to reduce swelling in the brain.,You may experience a headache, nausea, or increased thirst during infusion.,Report any signs of allergic reaction (rash, itching, difficulty breathing) immediately.,You will be monitored with blood tests to check kidney function and electrolyte levels.,Avoid rapid position changes to prevent dizziness due to fluid shifts.,Do not stop this medication abruptly; follow your healthcare provider's instructions.
This medication may cause increased thirst and frequent urination.,Report any chest pain, difficulty breathing, or swelling of ankles/legs.,Avoid consuming salty foods to prevent fluid retention.,Do not stop taking without consulting your doctor.,Inform your doctor if you have kidney disease, heart failure, or are on a low-salt diet.
No interactions on record
"Concomitant use of clonidine and mannitol may potentiate the hypotensive effect of clonidine, leading to an increased risk of severe hypotension, syncope, and orthostatic hypotension. Mannitol, an osmotic diuretic, can cause volume depletion and electrolyte disturbances, which may exacerbate clonidine's sympatholytic effects on blood pressure regulation. This interaction is particularly concerning in patients with pre-existing cardiovascular conditions or those receiving other antihypertensive agents."
"Mannitol, an osmotic diuretic, induces intravascular volume expansion followed by diuresis, which can cause electrolyte disturbances, particularly hypokalemia and hypomagnesemia. Nifedipine, a calcium channel blocker, can further lower blood pressure through vasodilation. The combination may enhance the hypotensive effect and increase the risk of arrhythmias due to electrolyte imbalances."
"Coadministration of candesartan cilexetil, an angiotensin II receptor blocker (ARB), with mannitol, an osmotic diuretic, can result in an additive hypotensive effect due to overlapping mechanisms that reduce blood pressure. Mannitol increases renal water excretion, decreasing plasma volume and preload, while candesartan inhibits angiotensin II-mediated vasoconstriction and aldosterone secretion, leading to vasodilation and reduced afterload. This combined effect may predispose patients to symptomatic hypotension, especially in those with volume depletion or renal impairment."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OSMITROL 10% IN WATER IN PLASTIC CONTAINER vs MANNITOL 10%, answered by our medical review team.
OSMITROL 10% IN WATER IN PLASTIC CONTAINER is a Osmotic Diuretic that works by Increases plasma osmolality, drawing water from tissues into the bloodstream, thereby reducing intracranial pressure and cerebral edema.. MANNITOL 10% is a Osmotic Diuretic that works by Mannitol is an osmotic diuretic that increases urinary output by raising the osmolarity of glomerular filtrate, thereby reducing tubular reabsorption of water and solutes. It also reduces cerebral edema by creating an osmotic gradient across the blood-brain barrier, drawing water from brain tissue into plasma.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OSMITROL 10% IN WATER IN PLASTIC CONTAINER and MANNITOL 10% depend on the specific clinical indication. These are both Osmotic Diuretic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OSMITROL 10% IN WATER IN PLASTIC CONTAINER is: Initial: 0.25–1 g/kg (25–100 m L of 10% solution) IV over 30–60 minutes. May repeat every 6–12 hours if needed. Typical adult dose: 50–100 g IV. Maximum: 2 g/kg per dose.. The standard adult dose of MANNITOL 10% is: 0.25-2 g/kg intravenously as a 10% solution over 30-60 minutes, typically 50-100 g every 6-8 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OSMITROL 10% IN WATER IN PLASTIC CONTAINER and MANNITOL 10% in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OSMITROL 10% IN WATER IN PLASTIC CONTAINER is classified as Category C. Osmitrol 10% (mannitol) is a hyperosmolar agent. There are no adequate and well-controlled studies in pregnant women. Animal studies have not been conducted. In first trimester, us. MANNITOL 10% is classified as Category A/B. Mannitol is a pregnancy category C drug. First trimester: Limited human data; animal studies indicate potential for fetal harm at high doses due to osmotic effects, but risk with c. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.